View More 2019, Scientific Sessions, Session Coverage

Results from TrialNet, RISE, DECLARE-TIMI 58, and REWIND trials to be presented Sunday


Estimated Read Time:

2 minutes

Sunday will feature more highly anticipated study announcements than any other day of the 79th Scientific Sessions. Here’s the schedule of Sunday sessions featuring major study results.

8:00 a.m. – 10:00 a.m.

TrialNet—New Therapeutic Approaches and Insights for Type 1 Diabetes

S-153 (South, Upper Mezzanine Level)

Where are we with disease-modifying therapy in type 1 diabetes? This session will present clinical and mechanistic results from TrialNet’s landmark Teplizumab Prevention Trial in individuals with multiple antibodies and abnormal glucose tolerance. The question for this study is whether treatment at early stages of disease can delay progression to clinical (stage 3) type 1 diabetes. Two-year clinical results from TrialNet’s Low Dose ATG and GSCF trial in new-onset diabetes will also be presented, as well as mechanistic data from TrialNet’s Natural History and Immune effects of Oral Insulin studies.

12:00 p.m. – 1:00 p.m.

Results and Comparisons from the RISE Clinical Trial—Adult Medication Study

S-157 (South, Upper Mezzanine Level)

Restoring Insulin Secretion (RISE) is a group of three studies, which includes the Adult Medication Study. In this study, adults with impaired glucose tolerance or recently diagnosed type 2 diabetes not receiving any medications have been randomized to one of four intervention groups to determine whether it’s possible to slow the loss of islet beta-cell function. Study results will be compared to youth with the same glucose tolerance abnormalities and thus highlight similarities and differences in the pathogenesis of the disease in the two age groups, as well as the response to interventions aimed at preserving beta-cell function.

2:15 p.m. – 4:15 p.m.


W-3001 (West, Level 3)

The Dapagliflozin Effect on Cardiovascular Events (DECLARE-TIMI 58) trial is the first cardiovascular outcome study to enroll a large cohort of diabetes patients with risk factors for atherosclerotic cardiovascular disease (ASCVD) and a large cohort of diabetes patients with known ASCVD. The session will cover the primary endpoints as well as subanalyses, including extensive discussion on renal endpoints and an in-depth review of the multiple safety aspects of dapagliflozin explored in the trial.

4:30 p.m. – 6:30 p.m.

Once-Weekly Dulaglutide and Major Cardiovascular Events—Results of the REWIND Trial

W-3001 (West, Level 3)

There have been five large, published randomized control trials on the effect of GLP-1 receptor agonists in patients with type 2 diabetes who have had a cardiovascular event and who also have a high prevalence of cardiovascular disease at baseline. The Researching CV Events with a Weekly Incretin in Diabetes (REWIND) trial was designed to test the long-term cardiovascular effect of the GLP-1 receptor agonist dulaglutide in a lower-risk group of 9,901 people, who are more representative of those in a general practice with type 2 diabetes.